Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer’s disease

Monoamine oxidase–B (MAO-B) has recently emerged as a potential therapeutic target for Alzheimer’s disease (AD) because of its association with aberrant γ-aminobutyric acid (GABA) production in reactive astrocytes. Although short-term treatment with irreversible MAO-B inhibitors, such as selegiline,...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Jong-Hyun, Ju, Yeon Ha, Choi, Ji Won, Song, Hyo Jung, Jang, Bo Ko, Woo, Junsung, Chun, Heejung, Kim, Hyeon Jeong, Shin, Su Jeong, Yarishkin, Oleg, Jo, Seonmi, Park, Mijeong, Yeon, Seul Ki, Kim, Siwon, Kim, Jeongyeon, Nam, Min-Ho, Londhe, Ashwini M., Kim, Jina, Cho, Sung Jin, Cho, Suengmok, Lee, Changho, Hwang, Sung Yeoun, Kim, Sang Wook, Oh, Soo-Jin, Cho, Jeiwon, Pae, Ae Nim, Lee, C. Justin, Park, Ki Duk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426469/
https://www.ncbi.nlm.nih.gov/pubmed/30906861
http://dx.doi.org/10.1126/sciadv.aav0316

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426469/
https://www.ncbi.nlm.nih.gov/pubmed/30906861
http://dx.doi.org/10.1126/sciadv.aav0316

Ejemplares similares